Literature DB >> 209113

Direct measurement of apoprotein B specific activity in 125I-labeled lipoproteins.

N A Le, J S Melish, B C Roach, H N Ginsberg, W V Brown.   

Abstract

A method for determining apoprotein B specific activity in radioiodinated lipoproteins is described and validated. It utilizes organic solvents and tetramethylurea in the isolation of apoprotein B from other radiolabeled contaminants, both lipid and protein, in exogenously labeled VLDL. The contaminants are also removed from those lipoprotein classes subsequently derived from VLDL, namely IDL and LDL. The procedure requires approximately 50 microgram of apoB per analysis, allowing specific activity determinations in triplicate on 3-ml plasma samples with a standard error of less than 6%. Finally, data from a study of apoprotein B turnover in VLDL, IDL, and LDL in a human subject is presented to demonstrate the potential of this method in further elucidating the kinetic interrelationships between these lipoprotein classes.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 209113

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  11 in total

1.  Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.

Authors:  H N Ginsberg; N A Le; I J Goldberg; J C Gibson; A Rubinstein; P Wang-Iverson; R Norum; W V Brown
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

2.  Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss.

Authors:  H N Ginsberg; N A Le; J C Gibson
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

3.  Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase.

Authors:  A Rubinstein; J C Gibson; J R Paterniti; G Kakis; A Little; H N Ginsberg; W V Brown
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

4.  Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis.

Authors:  H N Ginsberg; N A Le; M P Short; R Ramakrishnan; R J Desnick
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

5.  Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease.

Authors:  Y A Kesäniemi; W F Beltz; S M Grundy
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

6.  Lipoprotein metabolism during acute inhibition of lipoprotein lipase in the cynomolgus monkey.

Authors:  I J Goldberg; N A Le; H N Ginsberg; R M Krauss; F T Lindgren
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

7.  Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey.

Authors:  I J Goldberg; N A Le; J R Paterniti; H N Ginsberg; F T Lindgren; W V Brown
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

8.  Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans.

Authors:  G F Lewis; K D Uffelman; L W Szeto; B Weller; G Steiner
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

9.  Diversity in expression of heterozygous familial hypercholesterolemia. Characterization of a unique kindred.

Authors:  R A Levy; R E Ostlund; C F Semenkovich; J L Witztum
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

10.  Nonuniform radiolabeling of VLDL apolipoprotein B: implications for the analysis of studies of the kinetics of the metabolism of lipoproteins containing apolipoprotein B.

Authors:  R Ramakrishnan; Y Arad; S Wong; H N Ginsberg
Journal:  J Lipid Res       Date:  1990-06       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.